

CannPal Animal Therapeutics Ltd

11:53 03 Sep 2018

CannPal Animal Therapeutics commences dog pain control study

CannPal Animal Therapeutics Ltd (ASX:CP1) has commenced its phase Ib study for its lead drug candidate CPAT-01D, a cannabis-derived pain control for dogs.

48 beagles and foxhounds of both sexes in wide weight and age ranges have been enrolled after clinical screening and examination.

The live phase of the study is expected to be completed late in the coming December quarter 2018.

READ: CannPal Animal Therapeutics receives approval to advance clinical studies

CannPal's managing director Layton Mills said: "It is excellent to see the significant progress we are making with CPAT-01, and the quick turn-around time between phase Ia and phase Ib.

"CPAT-01 has the potential to offer a new solution for dogs that suffer from painful conditions and we look forward to rapidly progressing through phase II of this exciting research, at the completion of our phase I studies."

Phase 1B: study design	Phase 1B: endpoints
<ul style="list-style-type: none"> Dose ranging + pharmacokinetic + safety study 48 dogs (40 treated / 8 control) 1 NSW purpose-built research site Mixed beagles and foxhounds Various weight, age, and sexes 	<ul style="list-style-type: none"> Pivotal GLP pharmacokinetic data to support regulatory submissions. Early indication of the dose range Cannabinoid impact on identified gene expression targets Tolerability at up to 5x estimated dose of THC and CBD

Phase Ib is a continuation of the pharmacokinetic and safety study which started earlier in 2018 and showed excellent safety and tolerability for CPAT-01.

It builds on the pilot data already generated and includes additional endpoints.

Preparing for an application the FDA

With the results from these phase Ia and Ib studies, Cannpal plans to prepare to file an Investigational New Animal Drug (INAD) application with the US Food and Drug Administration (FDA).

It will also begin designing the protocol for the company's pilot dose determination study to commence in the June half of 2019, which will include client-owned animals with osteoarthritis.

Price: 0.14

Market Cap: \$13.04 m

1 Year Share Price Graph



Share Information

Code: CP1

Listing: ASX

52 week High Low
0.2 0.069

Sector: Cannabis

Website: www.cannpal.com

Company Synopsis:

CannPal Animal Therapeutics Ltd (ASX:CP1) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

READ: CannPal Animal Therapeutics teams up with University of Melbourne

Last month, CannPal entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.

Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol treatment for epilepsy in dogs in 2019.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).